1. Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats;Harriman;Proc Natl Acad Sci U S A,2016
2. The Nimbus Experiment: Structure-Based Drug Deals;Booth,2013
3. BIO: Nimbus CEO Keiper: ‘we’re not just a one-hit wonder’;Al Idrus,2020
4. Morphic therapeutic announces first healthy volunteers dosed in phase 1 clinical trial of MORF-057;BioSpace,2020
5. Relay therapeutics announces a worldwide license and collaboration agreement with genentech for RLY-1971;Therapeutics, R. & Inc,2020